PH12020552135A1 - Kdm1a inhibitors for the treatment of disease - Google Patents

Kdm1a inhibitors for the treatment of disease

Info

Publication number
PH12020552135A1
PH12020552135A1 PH12020552135A PH12020552135A PH12020552135A1 PH 12020552135 A1 PH12020552135 A1 PH 12020552135A1 PH 12020552135 A PH12020552135 A PH 12020552135A PH 12020552135 A PH12020552135 A PH 12020552135A PH 12020552135 A1 PH12020552135 A1 PH 12020552135A1
Authority
PH
Philippines
Prior art keywords
treatment
methods
disease
kdm1
inhibitors
Prior art date
Application number
PH12020552135A
Other languages
English (en)
Inventor
Amy E Tapper
Cassandra Celatka
Michael Clare
Jr Hugh Y Reinhoff
Original Assignee
Imago Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imago Biosciences Inc filed Critical Imago Biosciences Inc
Publication of PH12020552135A1 publication Critical patent/PH12020552135A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH12020552135A 2018-05-11 2020-12-11 Kdm1a inhibitors for the treatment of disease PH12020552135A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862670323P 2018-05-11 2018-05-11
PCT/US2019/032043 WO2019217972A1 (en) 2018-05-11 2019-05-13 Kdm1a inhibitors for the treatment of disease

Publications (1)

Publication Number Publication Date
PH12020552135A1 true PH12020552135A1 (en) 2021-06-21

Family

ID=68468431

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020552135A PH12020552135A1 (en) 2018-05-11 2020-12-11 Kdm1a inhibitors for the treatment of disease

Country Status (13)

Country Link
US (2) US11578059B2 (enExample)
EP (1) EP3790867B1 (enExample)
JP (1) JP7450559B2 (enExample)
KR (1) KR102684364B1 (enExample)
CN (1) CN112513020B (enExample)
AU (1) AU2019265022B2 (enExample)
BR (1) BR112021001066A2 (enExample)
CA (1) CA3103392A1 (enExample)
ES (1) ES2977656T3 (enExample)
IL (1) IL279260B2 (enExample)
PH (1) PH12020552135A1 (enExample)
SG (1) SG11202012289UA (enExample)
WO (1) WO2019217972A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2734209T3 (es) 2013-08-06 2019-12-04 Imago Biosciences Inc Inhibidores de KDM1A para el tratamiento de enfermedades
CA2976350C (en) 2015-02-12 2023-09-19 Hugh Young Rienhoff, Jr. Kdm1a inhibitors for the treatment of disease
CN111194306B (zh) 2016-08-16 2023-05-16 伊美格生物科学公司 用于制备kdm1a抑制剂的方法和过程
EP3790867B1 (en) 2018-05-11 2024-03-27 Imago Biosciences Inc. Kdm1a inhibitors for the treatment of disease
KR20220113753A (ko) * 2019-12-09 2022-08-16 이마고 바이오사이언시즈 인코포레이티드 골수증식성 신생물의 치료를 위한 리신-특이적 히스톤 데메틸라제 억제제
US20240216357A1 (en) * 2021-03-24 2024-07-04 Sichuan Huiyu Pharmaceutical Co., Ltd. Polycyclic compound and application thereof
CN114591324B (zh) * 2021-03-30 2023-05-05 深圳微芯生物科技股份有限公司 一类吡嗪酮衍生物、其制备及其应用
US20250073232A1 (en) 2021-04-08 2025-03-06 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for treating myeloid cancers
US20250295660A1 (en) 2022-05-09 2025-09-25 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
EP4522136A1 (en) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
US20260085082A1 (en) * 2022-12-23 2026-03-26 Imago Biosciences, Inc. Kdm1a inhibitors for the treatment of disease

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006037028A2 (en) * 2004-09-24 2006-04-06 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus
MX2009008531A (es) * 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
JP5140154B2 (ja) * 2007-06-27 2013-02-06 アストラゼネカ・アクチエボラーグ ピラジノン誘導体および肺疾患の処置におけるそれらの使用
EP2198018B1 (en) 2007-09-13 2013-11-20 Codexis, Inc. Ketoreductase polypeptides for the reduction of acetophenones
HUE027683T2 (en) 2007-10-01 2016-10-28 Codexis Inc Ketoreductase polypeptides for the production of azetidinone
WO2010025287A2 (en) 2008-08-27 2010-03-04 Codexis, Inc. Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
EP2177502A1 (en) 2008-10-17 2010-04-21 Oryzon Genomics, S.A. Compounds and their use
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
JPWO2010143582A1 (ja) 2009-06-11 2012-11-22 公立大学法人名古屋市立大学 フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
US8859555B2 (en) 2009-09-25 2014-10-14 Oryzon Genomics S.A. Lysine Specific Demethylase-1 inhibitors and their use
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
CA2796726C (en) 2010-04-19 2021-02-16 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
BR112012027062B8 (pt) 2010-04-20 2021-05-25 Fond Ieo composto, processo para a preparação de um composto e usos do mesmo
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
BR112013002164B1 (pt) 2010-07-29 2021-11-09 Oryzon Genomics S.A. Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica
WO2012034116A2 (en) 2010-09-10 2012-03-15 The Johns Hopkins University Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
WO2012047852A2 (en) 2010-10-07 2012-04-12 The J. David Gladstone Institutes Compositions and methods for modulating immunodeficiency virus transcription
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012071469A2 (en) 2010-11-23 2012-05-31 Nevada Cancer Institute Histone demethylase inhibitors and uses thereof for treatment o f cancer
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
EP2712316A1 (en) 2011-02-08 2014-04-02 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
PH12013501871A1 (en) 2011-03-25 2019-06-03 Glaxosmithkline Ip No 2 Ltd Cyclopropylamines as lsd1 inhibitors
PE20141202A1 (es) 2011-08-09 2014-10-03 Takeda Pharmaceutical Compuesto de ciclopropanoamina
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
JP6046154B2 (ja) 2011-10-20 2016-12-14 オリソン ヘノミクス エセ． アー． Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物
WO2014084298A1 (ja) 2012-11-28 2014-06-05 京都府公立大学法人 リシン構造を有するｌｓｄ1選択的阻害薬
EP2740474A1 (en) 2012-12-05 2014-06-11 Instituto Europeo di Oncologia S.r.l. Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
WO2014164867A1 (en) 2013-03-11 2014-10-09 Imago Biosciences Kdm1a inhibitors for the treatment of disease
CA2916533C (en) 2013-06-25 2022-12-20 University Of Canberra Methods and compositions for modulating cancer stem cells
ES2734209T3 (es) 2013-08-06 2019-12-04 Imago Biosciences Inc Inhibidores de KDM1A para el tratamiento de enfermedades
EP3105218B1 (en) 2014-02-13 2019-09-25 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
CN121203988A (zh) 2014-04-22 2025-12-26 C-乐克塔股份有限公司 酮还原酶
DK3160956T3 (da) * 2014-06-27 2020-08-31 Celgene Quanticel Res Inc Inhibitorer af lysin-specifik demethylase-1
CA2976350C (en) * 2015-02-12 2023-09-19 Hugh Young Rienhoff, Jr. Kdm1a inhibitors for the treatment of disease
WO2017075367A1 (en) * 2015-10-28 2017-05-04 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
US20190070172A1 (en) 2015-11-05 2019-03-07 Imago Biosciences, Inc. Lysine-specific histone demethylase as a novel therapeutic target in myeloproliferative neoplasms
US9809541B2 (en) * 2015-12-29 2017-11-07 Mirati Therapeutics, Inc. LSD1 inhibitors
PT3455204T (pt) * 2016-05-09 2026-01-27 Jubilant Epicore LLC Compostos de ciclopropil-amida como inibidores duplos de lsd1/hdac
WO2018035249A1 (en) 2016-08-16 2018-02-22 Imago Biosciences, Inc. Compositions and methods for producing stereoisomerically pure aminocyclopropanes
CN111194306B (zh) 2016-08-16 2023-05-16 伊美格生物科学公司 用于制备kdm1a抑制剂的方法和过程
MA51507A (fr) 2016-12-09 2020-11-11 Constellation Pharmaceuticals Inc Marqueurs pour un traitement personnalisé du cancer avec des inhibiteurs de lsd1
EP3790867B1 (en) 2018-05-11 2024-03-27 Imago Biosciences Inc. Kdm1a inhibitors for the treatment of disease

Also Published As

Publication number Publication date
AU2019265022B2 (en) 2024-08-15
EP3790867A4 (en) 2021-10-13
US11578059B2 (en) 2023-02-14
IL279260B1 (en) 2024-06-01
IL279260B2 (en) 2024-10-01
ES2977656T3 (es) 2024-08-28
CN112513020A (zh) 2021-03-16
CN112513020B (zh) 2024-02-23
IL279260A (en) 2021-01-31
KR102684364B1 (ko) 2024-07-11
SG11202012289UA (en) 2021-01-28
US20230250090A1 (en) 2023-08-10
BR112021001066A2 (pt) 2021-04-20
US11932629B2 (en) 2024-03-19
EP3790867B1 (en) 2024-03-27
JP7450559B2 (ja) 2024-03-15
KR20210008064A (ko) 2021-01-20
EP3790867A1 (en) 2021-03-17
US20210115023A1 (en) 2021-04-22
AU2019265022A1 (en) 2021-01-07
JP2021521266A (ja) 2021-08-26
CA3103392A1 (en) 2019-11-14
WO2019217972A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
PH12020552135A1 (en) Kdm1a inhibitors for the treatment of disease
EP4559902A3 (en) Kdm1a inhibitors for the treatment of disease
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
CR20210415A (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidoria en cdk2
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
ZA201906269B (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
SA519401970B1 (ar) مثبطات حلقية غير متجانسة لناقل مونوكربوكسيلات 4
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MX2016001587A (es) Inhibidores de kdm1a para el tratamiento de enfermedades.
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
MX2017004128A (es) Derivados de diarilurea como inhibidores de quinasa p38.
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
WO2016037157A3 (en) Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
JOP20180094A1 (ar) مركب حلقي غير متجانس كمثبط بروتين كيناز
EP4183806A3 (en) Glycan-interacting compounds and methods of use
WO2016004413A3 (en) Gls1 inhibitors for treating disease
MX392524B (es) Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar
MX2018016127A (es) Inhibidores de pde9 para el tratamiento de enfermedades perifericas.
TW201625535A (en) Inhibitors of histone demethylases
MX2016014436A (es) Derivados de heterociclil-butanamida.
MX2019012176A (es) Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer